Abstract
Lysophosphatidic acid (LPA) and sphingosine 1-phosphate (S1P) are naturally arising bioactive lipids. The roles of LPA and S1P in angiogenesis, tumor growth and metastasis have recently emerged. Blood platelets are an important source of LPA and S1P in the organism. However, other types of cells including cancer cells expressing autotaxin and sphingosine kinases have the capacity to produce LPA and S1P, respectively. During the past decade, studies revealed that LPA and S1P interact with a large series of G-protein-coupled receptors, at least seven for LPA (LPA1-5, GPR-87, P2Y5) and five for S1P (S1P1-5). This may account for the wide variety of cell types reacting to LPA and S1P stimulation and for the wide range of cellular functions controlled by these lysophospholipids such as proliferation, survival and motility. Genetic and pharmacological approaches were developed to block the activities of LPA or S1P in the context of cancer progression. This article presents recent findings based on extensive cell culture experiments and preliminary in vivo studies which demonstrate that targeting the lysophospholipid tracks would be extremely beneficial for patients suffering from cancer.
Keywords: Lysophosphatidic acid, sphingosine 1-phosphate, autotaxin, spkingosine kinase, antagonists, receptors, cancer cells
Anti-Cancer Agents in Medicinal Chemistry
Title: Novel Implications for Lysophospholipids, Lysophosphatidic Acid and Sphingosine 1-Phosphate, as Drug Targets in Cancer
Volume: 9 Issue: 4
Author(s): Olivier Peyruchaud
Affiliation:
Keywords: Lysophosphatidic acid, sphingosine 1-phosphate, autotaxin, spkingosine kinase, antagonists, receptors, cancer cells
Abstract: Lysophosphatidic acid (LPA) and sphingosine 1-phosphate (S1P) are naturally arising bioactive lipids. The roles of LPA and S1P in angiogenesis, tumor growth and metastasis have recently emerged. Blood platelets are an important source of LPA and S1P in the organism. However, other types of cells including cancer cells expressing autotaxin and sphingosine kinases have the capacity to produce LPA and S1P, respectively. During the past decade, studies revealed that LPA and S1P interact with a large series of G-protein-coupled receptors, at least seven for LPA (LPA1-5, GPR-87, P2Y5) and five for S1P (S1P1-5). This may account for the wide variety of cell types reacting to LPA and S1P stimulation and for the wide range of cellular functions controlled by these lysophospholipids such as proliferation, survival and motility. Genetic and pharmacological approaches were developed to block the activities of LPA or S1P in the context of cancer progression. This article presents recent findings based on extensive cell culture experiments and preliminary in vivo studies which demonstrate that targeting the lysophospholipid tracks would be extremely beneficial for patients suffering from cancer.
Export Options
About this article
Cite this article as:
Peyruchaud Olivier, Novel Implications for Lysophospholipids, Lysophosphatidic Acid and Sphingosine 1-Phosphate, as Drug Targets in Cancer, Anti-Cancer Agents in Medicinal Chemistry 2009; 9 (4) . https://dx.doi.org/10.2174/1871520610909040381
DOI https://dx.doi.org/10.2174/1871520610909040381 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Phytoestrogens: Pharmacological and Therapeutic Perspectives
Current Drug Targets Potential of Plant-Derived Natural Products in the Treatment of Leukemia and Lymphoma
Current Drug Targets Theranostic Radiopharmaceuticals Targeting Cancer-Associated Fibroblasts
Current Radiopharmaceuticals Is the Vagina an Adequate Route for the Administration of Hormonal Contraceptives?
Current Drug Metabolism A Mini-review on HER2 Positive Breast Cancer and its Metastasis: Resistance and Treatment Strategies
Current Nanomedicine Combined Effect of Parthenolide and Various Anti-cancer Drugs or Anticancer Candidate Substances on Malignant Cells in vitro and in vivo
Mini-Reviews in Medicinal Chemistry Role of Mismatch Repair and MGMT in Response to Anticancer Therapies
Anti-Cancer Agents in Medicinal Chemistry The Current View on the Helicase Activity of RNA Helicase A and Its Role in Gene Expression
Current Protein & Peptide Science The Post Hoc Use of Randomised Controlled Trials to Explore Drug Associated Cancer Outcomes: Methodological Challenges
Current Drug Safety Recent Advances in Minimal Access Surgery for Infants and Children
Current Pediatric Reviews A Review on Synthetic and Natural Steroid Dimers: 1997-2006
Current Medicinal Chemistry BRCA1-Associated Triple-Negative Breast Cancer and Potential Treatment for Ruthenium-Based Compounds
Current Cancer Drug Targets c-Myc: Linking Transformation and Genomic Instability
Current Molecular Medicine Psychoimmunological Analysis of Cancer Patients: Correlation with the Prognosis
Current Aging Science Novel Non-Steroidal Anti-Inflammatory Drugs: What we have Learned from Animal Studies
Current Drug Targets - Inflammation & Allergy New Optical Molecular Imaging Systems
Current Pharmaceutical Biotechnology Epigenetic Variation and Customising Nutritional Intervention
Current Pharmacogenomics and Personalized Medicine Antibody Fragments as Potential Biopharmaceuticals for Cancer Therapy: Success and Limitations
Current Medicinal Chemistry Patents on Non-Viral Mediated Gene Delivery
Recent Patents on DNA & Gene Sequences A Review of Natural and Modified Betulinic, Ursolic and Echinocystic Acid Derivatives as Potential Antitumor and Anti-HIV Agents
Mini-Reviews in Medicinal Chemistry